middle.news
How Bioxyne’s $17.2M Quarter Signals a Psychedelic and Cannabis Breakthrough
8:36am on Wednesday 28th of January, 2026 AEDT
•
Healthcare
Read Story
How Bioxyne’s $17.2M Quarter Signals a Psychedelic and Cannabis Breakthrough
8:36am on Wednesday 28th of January, 2026 AEDT
Key Points
Record $17.2 million quarterly revenue, up 21% from prior quarter
Positive operating cash flow of $2.5 million
Dual listing on Frankfurt Stock Exchange enhances European access
First Australian-made GMP MDMA capsules supplied for clinical trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
BIOXYNE (ASX:BXN)
OPEN ARTICLE